Compare ResMed Inc. (RMD) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs S&P Global Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while S&P Global Inc trades at $404.47 (market cap $118.72B). The key difference: S&P Global Inc is far larger — about 3.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and S&P Global Inc for 123 Days on average.
| RMD | SPGI | |
|---|---|---|
Market Cap | $31.89B | $118.72B |
Volume | 618,314 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $277.88 | $517.92 |
52-Week Low | $182.82 | $370.42 |
Typical Hold Time | 51 Days | 123 Days |
Enterprise Value | $31.24B | $130.21B |
Dividend Yield | 1.16% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 30.5% net margins and consistent revenue growth from $15.3B in 2025 to projected $16.1B in 2026. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The outlook remains positive given the company's dominant market position and financial strength, though technical weakness and high valuation multiples present near-term risks. Long-term growth drivers include AI integration and strategic acquisitions, while risks include market sensitivity to economic cycles and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
